The registrant is qualified to purchase and use the following medications only:

- Lignocaine injection up to 2% in plain solution or containing adrenaline 1:200,000;
- Mepivacaine injection in plain solution up to 2%;
- Prilocaine injection up to 2% in plain solution or containing adrenaline 1:200,000;
- Bupivacaine injection up to 0.5% in plain solution or containing adrenaline 1:200,000;
- Ropivacaine injection up to 7.5mg/ml
- Amoxycillin with Potassium Clavulanate - up to a ten day course of treatment per patient
- Cephalexin - up to a ten day course of treatment per patient
- Dexamethasone Sodium Phosphate injection 4mg/ml - single administration per patient
- Diclofenac Sodium - up to 20 doses per patient
- Erythromycin - up to a ten day course of treatment per patient
- Flucloxacillin
  - up to a twelve day course of treatment per patient, consisting of a six day course which can be followed by a further six day course, if necessary, following a consultation
- Lorazepam - one dose per patient
- Naproxen - up to 20 doses per patient
- Paracetamol 500mg with Codeine Phosphate 15mg per dose - up to 20 doses per patient
- Paracetamol 500 mg with Codeine Phosphate 30mg per dose - up to 20 doses per patient
- Methoxyflurane in a Penthrox® inhaler

The authority to purchase and use these medicines is conditional on the following:

(a) they are only to be used as part of the surgical treatment of your patients;

(b) any significant adverse effects of their use are to be reported to the Chief Executive Officer of the Department of Health;

(c) records must be kept in such a way that ensures transparency of supply. These records are to be made available to the Department of Health when requested;

(d) all labels must be in compliance with the Poisons Regulations and written instructions must be given to patients for each drug used.